Back to top
more

Trevena (TRVN)

(Delayed Data from NSDQ)

$0.24 USD

0.24
482,045

+0.01 (5.75%)

Updated Jul 12, 2024 04:00 PM ET

After-Market: $0.24 0.00 (-0.46%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value C Growth B Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 30% (75 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Puma Biotech's (PBYI) Nerlynx Gets Approval in Australia

by Zacks Equity Research

Puma Biotech (PBYI) gains an approval in Australia for Nerlynx as an extended adjuvant treatment in adult patients with early stage HER2-positive breast cancer.

Is Trevena (TRVN) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Is (TRVN) Outperforming Other Medical Stocks This Year?

PDL BioPharma (PDLI) Q4 Earnings Top Mark, Revenues Fall Y/Y

by Zacks Equity Research

PDL BioPharma's (PDLI) earnings exceed estimates in Q4. Lower royalties as well as weak product sales induce a downfall in year-over-year revenues.

Puma Biotech (PBYI) Up More Than 95% in 3 Months: Here's Why

by Zacks Equity Research

Sales of Puma Biotech's (PBYI) only marketed drug Nerlynx are impressive in Q4, improving from third-quarter 2018 levels.

Agenus Wins $7.5M Milestone Payment From Gilead, Stock Up

by Zacks Equity Research

Agenus (AGEN) gets a $7.5-million milestone payment from Gilead following the FDA acceptance of the company's IND filing for AGEN1423. Shares rise.

Will Trevena Continue to Surge Higher?

by Zacks Equity Research

As of late, it has definitely been a great time to be an investor in Trevena.

Implied Volatility Surging for Trevena (TRVN) Stock Options

by Zacks Equity Research

Investors need to pay close attention to Trevena (TRVN) stock based on the movements in the options market lately.

The Zacks Analyst Blog Highlights: Alder, Xenon, Spero and Trevena

by Zacks Equity Research

The Zacks Analyst Blog Highlights: Alder, Xenon, Spero and Trevena

Nitish Marwah headshot

4 Healthcare Stocks Thriving on Venture Capital Funding

by Nitish Marwah

A steady influx of foreign as well as domestic investments in U.S. healthcare has gone a long way in boosting gains for the space.

3 Biotech Stocks With Rising Estimates in the Past Month

by Zacks Equity Research

The biotech industry is performing reasonably well. Hence, it is a good idea to select stocks from the sector witnessing positive estimate revisions.

    Implied Volatility Surging for Trevena (TRVN) Stock Options

    by Zacks Equity Research

    Trevena (TRVN) needs investors to pay close attention to the stock based on moves in the options market lately.

      Trevena, Inc. (TRVN) Jumps: Stock Rises 11.7%

      by Zacks Equity Research

      Trevena, Inc. (TRVN) was a big mover last session, as the company saw its shares nearly 12% on the day amid huge volumes.

        Trevena Announces FDA Acceptance of Olinvo NDA, Shares Up

        by Zacks Equity Research

        FDA accepts Trevena's (TRVN) NDA for acute pain drug, Olinvo.

          Is a Beat in the Cards for Vertex (VRTX) in Q3 Earnings?

          by Zacks Equity Research

          Vertex's (VRTX) Kalydeco is expected to generate increased revenues following its label expansion in the third quarter of 2017.

            What Makes Trevena (TRVN) a Strong Sell?

            by Zacks Equity Research

            Trevena (TRVN) has witnessed a significant price decline in the past four weeks, and it has lately seen negative earnings estimate revisions as well.